Published: November 2024 | Last updated: May 2026
The link between HPV and anal cancer is stronger than the link between smoking and lung cancer. About 91% of anal cancers in the United States are caused by human papillomavirus, according to CDC surveillance data on HPV-attributable cancers. That number rises year over year as anal cancer itself becomes more common, with an estimated 11,270 new diagnoses projected in the U.S. for 2026 per American Cancer Society projections.
If you're reading this because you tested positive for HPV, had a partner test positive, or you're in a higher-risk group and want to understand what that means, you're in the right place. This article walks through how the biology works, who's at meaningfully elevated risk, what symptoms warrant a visit (and which usually don't), how anal cancer screening works in practice, and what prevention moves the dial.
How HPV causes anal cancer
HPV stands for human papillomavirus, a family of more than 200 viral strains, about 40 of which infect the anogenital area. Most of those 40 are low-risk: they may cause genital warts but don't drive cancer. A smaller subset, the high-risk strains, are oncogenic. Two of them, HPV-16 and HPV-18, are considered the highest-risk types and account for the bulk of HPV-driven cancers across affected anatomic sites.
The infection itself is common. CDC notes that nearly everyone who is not vaccinated will encounter HPV at some point in their lives. Most of those infections clear within one to two years and never cause disease. Cancer risk comes from persistence: when a high-risk strain stays in the same tissue for years instead of clearing.
In the anal canal, persistent high-risk HPV infects cells in a specific region called the anal transition zone, the area where the squamous cells of the lower anal canal meet the columnar cells of the rectum. This zone is biologically vulnerable for the same reason the cervical transition zone is: the cells are actively dividing, which makes viral integration easier. Over years, that integration causes the cells to acquire mutations, lose normal growth controls, and progress through stages of dysplasia.
Pathologists call these precancerous changes anal intraepithelial neoplasia, or AIN. AIN is graded from 1 (mild dysplasia, often regresses on its own) to 3 (severe dysplasia, also called high-grade squamous intraepithelial lesion or HSIL). A 2019 CDC MMWR report put the proportion of anal cancers attributable to HPV at 88% based on tumor genotyping; more recent CDC surveillance data places the figure at roughly 91%. The discrepancy reflects different time periods and methods, not a fundamental disagreement: anal cancer is overwhelmingly an HPV-caused disease.
The full timeline from initial HPV infection to invasive cancer typically runs 10 to 30 years in immunocompetent people. In people with weakened immunity (most importantly those living with HIV, but also organ transplant recipients on immunosuppressants), the timeline can compress to under a decade and the lifetime risk multiplies several-fold.
About 91% of anal cancers are thought to be caused by HPV.
Who is at meaningfully higher risk
Anal cancer is uncommon in the general population (roughly 1 to 2 cases per 100,000 people per year), but the risk is far from evenly distributed. A few groups carry most of the elevated risk, and the gap is large enough that it changes whether screening makes sense.
People living with HIV face the highest documented risk, particularly men who have sex with men. American Cancer Society notes that AIN, the precancerous lesion that can progress to anal cancer, is found more often in people with HIV and in men who have sex with men. The biology is straightforward: HIV-associated immune compromise lets persistent HPV infections progress through dysplasia more quickly, and AIN is the step on that road that can develop into invasive cancer if not caught.
Men who have sex with men, regardless of HIV status, also carry elevated baseline risk because receptive anal sex is an efficient route for the anal canal to acquire HPV. Cisgender women and transgender people who have had receptive anal sex share the same anatomically-driven exposure risk, although the population-level rates published in epidemiology data are usually broken out by sex and HIV status rather than sexual practice.
Other groups with elevated risk include:
- Solid organ transplant recipients on long-term immunosuppression. Risk is substantially increased over the general population.
- People with autoimmune conditions on immunosuppressive therapy, including some biologics for inflammatory bowel disease, rheumatoid arthritis, or lupus.
- Women with a history of HPV-related cervical, vaginal, or vulvar precancer or cancer. Field cancerization means the same high-risk strain may already be in the anal site.
- Anyone who smokes. Smoking impairs HPV clearance and meaningfully raises lifetime anal cancer risk in people who carry the virus.
What is not on this list matters too. Casual contact, shared toilet seats, and bath towels are not meaningful routes of HPV transmission. The virus requires sustained skin-to-skin contact with an infected mucosal or skin surface.
stdrapidtestkits.com sells a rapid at-home HPV test that uses a self-collected vaginal swab. It is validated for female anatomy only and screens for high-risk HPV strains at the cervical and vaginal sites. It does not test the anal canal. For anal-site screening (anal Pap, anal HPV swab, or high-resolution anoscopy) see a clinic equipped for that procedure. Our HPV kit is still useful as a baseline of your overall HPV status if you are a woman with risk factors for anal HPV, because the same high-risk strains often colonize multiple anogenital sites.
Symptoms worth attention (and what they usually are not)
Most anal symptoms are not cancer. Hemorrhoids, anal fissures, perianal abscesses, and benign skin tags account for the overwhelming majority of bleeding, pain, and lump complaints. The caveat is that anal cancer symptoms can look identical to common benign conditions, which is why delays in diagnosis are common.
The symptoms that should prompt a visit, especially if they last longer than two to three weeks or worsen instead of resolving:
- Rectal bleeding. Bright red blood on toilet paper or in the bowl is the most frequent presenting symptom of anal cancer. It is also the most frequent presentation of hemorrhoids. Do not self-diagnose; if it does not clear within a few weeks, have it evaluated.
- A persistent lump or thickening at or just inside the anal opening. Hemorrhoids and skin tags are common, but a lump that grows, does not resolve, or feels firm and fixed warrants imaging.
- Anal pain that does not fit the fissure pattern. Fissure pain is sharp during and after a bowel movement and resolves within minutes to hours. Persistent dull aching, a sense of fullness, or pain unrelated to defecation is different.
- Change in bowel habit. Narrowing of stools, new urgency, or new incontinence can reflect a tumor occupying space in the anal canal.
- Discharge, itching, or non-healing sores. Mucus or pus discharge that is not explained by an obvious infection, or a sore that does not heal in two to three weeks, should be examined.
- Swollen lymph nodes in the groin. A late but important sign. Worth checking sooner rather than later.
Almost none of these symptoms, on their own, mean cancer. They do mean a brief visual exam and digital rectal exam by a clinician are worth scheduling. If the exam is unremarkable, you have your reassurance. If it is not, you have the early diagnosis that drives the strong cure rate for early-stage anal cancer caught before spread.
Any anal bleeding, lump, or pain lasting more than three weeks needs an in-person exam. The same goes for unexplained groin lymph node swelling, persistent discharge, or a sore that does not heal. Most causes are benign, but the visit costs little and the early-diagnosis difference for anal cancer is large.
Anal cancer screening: anal Pap, HRA, and where they are available
Routine anal cancer screening is not recommended for the general population. The U.S. Preventive Services Task Force has not issued a screening recommendation because the population-level benefit is unclear. Specialty groups, however, have moved toward screening higher-risk populations after the 2022 ANCHOR trial (published in the New England Journal of Medicine) showed that treating high-grade anal precancer in people with HIV cut progression to cancer by roughly 57% compared with active monitoring.
Three screening tools matter in practice:
- Anal cytology (anal Pap). A clinician swabs the anal canal and the cells are examined for dysplasia. The procedure is brief and tolerable, similar in spirit to a cervical Pap. Abnormal results trigger high-resolution anoscopy.
- High-resolution anoscopy (HRA). A specialist uses a magnifying scope and acetic acid staining to identify and biopsy precancerous areas. HRA is the diagnostic gold standard for anal precancer and the procedure used to treat HSIL when it is found. The NCI notes that studies suggest using anoscopy to screen for anal cancer could reduce deaths in HIV-positive patients.
- Anal HPV testing. A swab tests for the presence of high-risk HPV in the anal canal. It does not replace cytology or HRA; it adds risk stratification.
The International Anal Neoplasia Society and several HIV-specialty groups now recommend anal Pap screening for people living with HIV starting around age 35 for men who have sex with men and age 45 for other adults with HIV. Some centers also screen MSM without HIV, women with prior cervical or vulvar precancer, and solid organ transplant recipients on a case-by-case basis.
Access is the practical problem. HRA-trained providers are concentrated in academic medical centers, large HIV clinics, and a few specialty colorectal practices. If you are in a higher-risk group, ask your primary care clinician for a referral to anal cancer screening, or contact a regional HIV clinic for guidance on local availability.
| Tool | Who performs it | What it detects | Abnormal result triggers |
|---|---|---|---|
| Anal Pap (cytology) | Primary care clinician or specialty clinic | Abnormal cells in the anal canal | Referral to high-resolution anoscopy |
| High-resolution anoscopy (HRA) | HRA-trained specialist | Precancerous and cancerous lesions; can biopsy and treat HSIL in-office | Office-based treatment or excision |
| Anal HPV testing | Specialty clinic | Presence of high-risk HPV strains in the anal canal | Adds risk context; used alongside cytology |
Prevention: what moves the dial
Four interventions have evidence behind them, listed roughly in order of impact.
HPV vaccination. The 9-valent HPV vaccine (Gardasil 9) protects against HPV-16, 18, 31, 33, 45, 52, and 58. Per CDC and ACIP guidance, routine vaccination is at age 11 to 12 (and can start at 9), with catch-up vaccination through age 26 and shared clinical decision-making for adults age 27 through 45. The vaccine works best before HPV exposure, but adults in the 27-to-45 range who have not been exposed to all nine strains can still benefit. Vaccine efficacy against persistent anal HPV infection has been high in clinical trial data.
Treating anal HSIL when found. The 2022 ANCHOR trial (published in the New England Journal of Medicine) showed that office-based treatment of biopsy-confirmed HSIL in people with HIV reduced progression to anal cancer by 57% compared with active monitoring. This is the strongest recent evidence that screening followed by treatment can prevent cancer in higher-risk groups.
Smoking cessation. Smokers carrying high-risk HPV clear the virus more slowly than non-smokers and have meaningfully higher anal cancer risk. Quitting at any age reduces the trajectory. If you smoke and have other anal cancer risk factors, smoking cessation is the largest single modifiable risk you can change.
Condoms and reduced number of partners. Condoms cut HPV transmission roughly in half during the acts they cover, but do not eliminate it because HPV lives on skin areas a condom does not reach. Fewer partners means fewer exposure events. Neither intervention is as protective as vaccination, but both are additive.
What does not have strong evidence behind it: dietary supplements (vitamins C, D, and zinc are commonly suggested but lack trial evidence for HPV clearance), most herbal protocols, and probiotic interventions. The supplement industry around HPV is large and largely unsupported by clinical trials. Eat well, sleep, exercise; that is the same general-health advice that supports immune function for any infection, and it is fine to follow, just do not substitute it for vaccination and screening.
Where at-home HPV testing fits
At-home HPV testing will not tell you whether you have anal cancer or anal precancer. The right tools for that are anal cytology and high-resolution anoscopy at a clinic. What at-home testing does do, for women, is give you a discreet way to check your high-risk HPV status without scheduling a clinic visit. That is useful as a baseline if you have risk factors for anal HPV (prior cervical or vulvar HPV precancer, HIV, immune suppression, smoking, history of receptive anal sex), because the same high-risk strains often colonize multiple anogenital sites and a positive at-home result can prompt the clinic conversation you might otherwise put off.
Our at-home rapid HPV test uses a self-collected vaginal swab and detects the presence of high-risk HPV in cervical and vaginal samples. It is validated for women only. We do not offer a male-compatible HPV self-test and we do not sell an anal-site HPV swab. For men in higher-risk groups concerned about anal HPV, the right next step is a clinic visit for an anal Pap and an HRA referral if indicated.
Frequently Asked Questions
- Can HPV cause anal cancer even if I have no symptoms?
- Yes. Most anal precancer (AIN and HSIL) and even early-stage anal cancer produce no symptoms at all, which is exactly why screening matters for higher-risk groups. By the time bleeding, pain, or a lump appears, the disease has typically been progressing silently for some time. Asymptomatic high-risk HPV infection is also extremely common; most adults will carry the virus at some point and never know.
- How long after HPV infection can anal cancer develop?
- The typical window from initial HPV infection to anal cancer is 10 to 30 years for people with healthy immune systems. HIV or long-term immunosuppression can compress that to under a decade. The more common outcome at any immune status is viral clearance within two years with no lasting disease.
- Does the HPV vaccine prevent anal cancer if I am already an adult?
- Through age 45 is the practical answer. ACIP recommends routine vaccination at age 11 to 12, catch-up vaccination through 26, and shared clinical decision-making for adults 27 to 45. Benefit drops as past exposure to vaccine-covered strains accumulates, so the conversation with your clinician centers on your individual exposure history rather than a hard age cutoff.
- Should men get anal cancer screening?
- Anal Pap screening starts around age 35 for men with HIV (especially men who have sex with men), per International Anal Neoplasia Society guidelines. HIV-negative MSM and men with other risk factors (immunosuppression, prior HPV-related disease) are evaluated case-by-case. There is no general-population screening recommendation for men outside higher-risk groups.
- Is an at-home HPV test enough if I am worried about anal HPV?
- Not on its own. Our at-home HPV test (and other at-home kits) uses a vaginal self-swab that screens the cervical and vaginal sites, not the anal canal. It can confirm whether you carry high-risk HPV in general, which is useful baseline context. For anal-site screening specifically you need anal cytology at a clinic, with HRA referral if abnormal.
- Can condoms fully protect me from anal HPV?
- Only partly. Condoms cut HPV transmission roughly in half during the acts they cover, but HPV lives on skin surfaces a condom does not reach, so transmission can still happen. Vaccination is meaningfully stronger; condoms are an additive layer rather than a standalone barrier.
- Are most anal symptoms cancer?
- No, almost never. The overwhelming majority of anal bleeding, pain, lumps, and itching come from hemorrhoids, fissures, abscesses, or benign skin conditions. The reason to have persistent symptoms (longer than two to three weeks) checked is that early-stage anal cancer carries a strong cure rate when caught before spread, and you cannot reliably tell the difference at home.
- How effective is treating anal precancer?
- Treatment cuts cancer progression substantially. The 2022 ANCHOR trial showed a 57% reduction in cancer development among people with HIV when biopsy-confirmed HSIL was treated in-office versus actively monitored. Outside HIV the randomized evidence is less complete, but the underlying principle (catch and remove high-grade precancer before it invades) is consistent across HPV-related cancers.
- U.S. Centers for Disease Control and Prevention. Cancers Linked with HPV Each Year. Source for the 91% anal cancer attributable fraction and annual U.S. case counts.
- U.S. Centers for Disease Control and Prevention. HPV: About. Source for the CDC statement that nearly everyone who is not vaccinated will encounter HPV at some point in their lives.
- American Cancer Society. Key Statistics for Anal Cancer. 2026 U.S. incidence and mortality projections (about 11,270 new cases, 1,700 deaths) and demographic patterns.
- American Cancer Society. About Anal Cancer. Squamous cell histology, AIN precursor lesions, and risk-factor overview including elevated AIN frequency in people with HIV and men who have sex with men.
- National Cancer Institute. Anal Cancer Prevention (PDQ). Source for HPV vaccination as prevention and the note that studies suggest anoscopy screening could reduce anal cancer deaths in HIV-positive patients.
- U.S. Centers for Disease Control and Prevention. HPV Vaccination. ACIP age recommendations for routine (11 to 12), catch-up (through 26), and shared decision-making (27 to 45) vaccination.
